Detail akcie Lexicon Pharma online

Business Summary: Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Lexicon Pharmaceuticals Inc revenues increased 60% to $49.8M. Net loss decreased 75% to $50.3M. Revenues reflect Licensing revenue increase of 80% to $45M, Royalties and other revenue increase of 95% to $156K. Lower net loss reflects Discovery, Devlopment & commercialization segment loss decrease of 75% to $48.9M.